SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Authors
Keywords
Blood pressure, Cardiovascular mortality, Empagliflozin, Haemodynamic, Heart failure, Renal dysfunction, Review, Sodium-glucose linked transporter-2, Type 2 diabetes
Journal
DIABETOLOGIA
Volume 59, Issue 7, Pages 1333-1339
Publisher
Springer Nature
Online
2016-04-25
DOI
10.1007/s00125-016-3956-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Blood Pressure Lowering in Type 2 Diabetes
- (2015) Connor A. Emdin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people
- (2015) Anoop Dinesh Shah et al. Lancet Diabetes & Endocrinology
- Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
- (2014) John J V McMurray et al. Lancet Diabetes & Endocrinology
- Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
- (2013) Steven P. Marso et al. AMERICAN HEART JOURNAL
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
- (2013) Bruce Neal et al. AMERICAN HEART JOURNAL
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
- (2013) William N Washburn et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
- (2013) Jan N. Basile JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial
- (2011) William T Abraham et al. LANCET
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
- (2009) Kausik K Ray et al. LANCET
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started